Published in Proc Natl Acad Sci U S A on July 15, 1992
Chronic herpesvirus reactivation occurs in aging. Exp Gerontol (2007) 1.99
"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin Microbiol Rev (1994) 1.54
Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers. J Virol (2003) 1.45
In vitro selection of RNA ligands for the ribosomal L22 protein associated with Epstein-Barr virus-expressed RNA by using randomized and cDNA-derived RNA libraries. J Virol (1995) 1.34
Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol (1993) 1.31
Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals. J Virol (1996) 1.17
Multiple Epstein-Barr virus infections in healthy individuals. J Virol (2003) 1.15
Unconventional processing of the 3' termini of the Epstein-Barr virus DNA polymerase mRNA. Proc Natl Acad Sci U S A (1993) 1.14
Epstein-Barr virus intrastrain recombination in oral hairy leukoplakia. J Virol (1994) 1.13
Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals. J Virol (1996) 1.02
The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. J Virol (1994) 1.00
Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains. J Virol (2000) 1.00
Novel intertypic recombinants of epstein-barr virus in the chinese population. J Virol (2000) 1.00
Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort. J Virol (1998) 1.00
Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences. J Virol (1996) 0.99
Epstein-Barr virus infection of Langerhans cell precursors as a mechanism of oral epithelial entry, persistence, and reactivation. J Virol (2007) 0.98
Identification of Epstein-Barr virus strain variants in hairy leukoplakia and peripheral blood by use of a heteroduplex tracking assay. J Virol (2002) 0.97
Virologic Diagnosis, Viral Monitoring, and Treatment of Epstein-Barr Virus Infectious Mononucleosis. Curr Infect Dis Rep (2004) 0.90
Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1,000 Genomes Project. Genome Biol Evol (2014) 0.89
Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus. J Virol (1996) 0.88
Autoantigenic proteins that bind recombinogenic sequences in Epstein-Barr virus and cellular DNA. Proc Natl Acad Sci U S A (1994) 0.87
Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection. Clin Diagn Lab Immunol (2004) 0.86
Points of recombination in Epstein-Barr virus (EBV) strain P3HR-1-derived heterogeneous DNA as indexes to EBV DNA recombinogenic events in vivo. J Virol (2008) 0.76
Epithelial cell retention of transcriptionally active, P3HR-1-derived heterogeneous Epstein-Barr virus DNA with concurrent loss of parental virus. J Virol (2011) 0.75
Epstein-Barr virus in the pathogenesis of oral cancers. Oral Dis (2017) 0.75
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A (1985) 8.19
Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc Natl Acad Sci U S A (1974) 5.54
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A (1984) 5.27
The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell (1986) 5.13
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A (1980) 5.02
Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med (1985) 4.78
Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. J Virol (1982) 4.65
Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med (1984) 4.47
Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol (1981) 4.38
DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative. Cell (1980) 4.14
Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol (1988) 3.84
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol (1990) 3.54
Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol (1991) 3.24
A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer (1985) 2.23
A cosmid vector that facilitates restriction enzyme mapping. Proc Natl Acad Sci U S A (1985) 2.21
The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer (1987) 2.16
Geographical prevalence of two types of Epstein-Barr virus. Virology (1986) 2.05
Detection of a second widespread strain of Epstein-Barr virus. Lancet (1989) 1.93
Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc Natl Acad Sci U S A (1990) 1.90
Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. J Gen Virol (1991) 1.70
The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. J Gen Virol (1991) 1.27
Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis (1990) 1.26
A transformation-incompetent, nuclear antigen 2-deleted Epstein-Barr virus associated with replicative infection. J Infect Dis (1991) 1.10
Genetic polymorphism of natural Epstein-Barr virus isolates from infectious mononucleosis patients and healthy carriers. J Virol (1988) 1.02
Defective viral DNA in Epstein-Barr virus-associated oral hairy leukoplakia. J Virol (1990) 1.00
Fragment length polymorphisms among independent isolates of Epstein-Barr virus from immunocompromised and normal hosts. J Infect Dis (1988) 0.99
Two strains of Epstein-Barr virus (B95-8 and a P3HR-1 subclone) that lack defective genomes induce early antigen and cause abortive infection of Raji cells. J Virol (1987) 0.99
Infection with two genotypes of Epstein-Barr virus in an infant with AIDS and lymphoma of the central nervous system. J Infect Dis (1986) 0.99
Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA (1988) 0.98
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood (1998) 6.26
Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J Virol (1980) 5.59
The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell (1986) 5.13
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A (1980) 5.02
Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med (1995) 4.62
Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med (1984) 4.47
DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative. Cell (1980) 4.14
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA (1986) 3.74
Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature (1984) 2.81
DNA of Epstein-Barr virus. III. Identification of restriction enzyme fragments that contain DNA sequences which differ among strains of Epstein-Barr virus. J Virol (1978) 2.76
Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A (1991) 2.74
Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science (1999) 2.61
Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A (1998) 2.49
Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med (1992) 2.48
Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. J Virol (1990) 2.43
Primary human T-lymphotropic virus type III infection. Ann Intern Med (1985) 2.40
Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol (2000) 2.21
Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex. N Engl J Med (1985) 2.20
Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology (2001) 2.19
The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer (1987) 2.16
Spinal Analgesia in Operative Obstetrics. Br Med J (1945) 2.16
Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol (1992) 2.14
Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol (1997) 2.05
Dental HIV transmission? Nature (1993) 2.04
Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol (1996) 2.03
The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol (1995) 2.02
Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis (1989) 1.99
Detection of a second widespread strain of Epstein-Barr virus. Lancet (1989) 1.93
Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol (1991) 1.91
Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc Natl Acad Sci U S A (1990) 1.90
Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet (1986) 1.88
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood (1998) 1.86
Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia. J Infect Dis (1995) 1.75
Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol (2003) 1.74
Human epithelial cell expression of an Epstein-Barr virus receptor. J Gen Virol (1987) 1.73
Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol (1994) 1.67
Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med (1988) 1.65
A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet (1986) 1.61
Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol (1995) 1.58
Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology (2000) 1.58
Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. J Virol (1995) 1.57
Epstein-Barr virus transcription in nasopharyngeal carcinoma. J Virol (1983) 1.57
Diphosphonate therapy of paget's disease of bone. J Clin Endocrinol Metab (1977) 1.50
Structural analyses of the Epstein-Barr virus BamHI A transcripts. J Virol (1995) 1.49
Peak selection from MALDI-TOF mass spectra using ant colony optimization. Bioinformatics (2007) 1.44
U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (1993) 1.43
Establishment and characterization of an Epstein-Barr virus spontaneously transformed lymphocytic cell line derived from a hairy cell leukemia patient. Leukemia (1991) 1.41
Diagnosis of pediatric human immunodeficiency virus infection by means of a commercially available polymerase chain reaction gene amplification. Arch Pediatr Adolesc Med (1996) 1.39
Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut (2006) 1.34
Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. Am J Trop Med Hyg (2001) 1.33
Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol (1999) 1.33
Prevalence of antibodies to hepatitis E in two rural Egyptian communities. Am J Trop Med Hyg (2000) 1.33
Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol (1993) 1.31
Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis (1998) 1.29
Interaction of Chlamydia trachomatis with human genital epithelium in culture. J Gen Microbiol (1986) 1.28
Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology (1999) 1.28
Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus. J Virol (1997) 1.28
Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J Virol (2000) 1.27
Epstein-Barr virus: structure of the viral DNA and analysis of viral RNA in infected cells. Biochim Biophys Acta (1979) 1.25
Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression. Mol Cell Biol (1998) 1.24
Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol (2007) 1.24
Detection of cell-free Epstein-Barr virus DNA in serum during acute infectious mononucleosis. J Infect Dis (1994) 1.23
EBV strain variation: geographical distribution and relation to disease state. Virology (1992) 1.23
Social cognition in attention-deficit hyperactivity disorder (ADHD). Neurosci Biobehav Rev (2009) 1.22
The Epstein-Barr virus 3.5-kilobase latent membrane protein 1 mRNA initiates from a TATA-Less promoter within the first terminal repeat. J Virol (1995) 1.22
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr (1994) 1.22
Concatameric replication of Epstein-Barr virus: structure of the termini in virus-producer and newly transformed cell lines. J Virol (1990) 1.21
Interactions between human granulocytes and Blastomyces dermatitidis. Infect Immun (1979) 1.21
The NPC derived C15 LMP1 protein confers enhanced activation of NF-kappa B and induction of the EGFR in epithelial cells. Oncogene (1998) 1.18
LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice. Oncogene (2006) 1.17
Epstein-Barr Virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis (1996) 1.16
Epstein-Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of China. Int J Cancer (1998) 1.14
Epstein-Barr virus intrastrain recombination in oral hairy leukoplakia. J Virol (1994) 1.13
Development of an assay that detects transcriptionally competent human immunodeficiency virus type one particles. J Virol Methods (1994) 1.12
A novel homozygous missense mutation of the leptin gene (N103K) in an obese Egyptian patient. Mol Genet Metab (2009) 1.12
Multiple sclerosis-like illness occurring with human immunodeficiency virus infection. Neurology (1989) 1.11
Excretion of the Epstein-Barr virus from the genital tract of men. J Infect Dis (1991) 1.10
A transformation-incompetent, nuclear antigen 2-deleted Epstein-Barr virus associated with replicative infection. J Infect Dis (1991) 1.10
The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex. Virology (1999) 1.10
Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol (1992) 1.09
Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal Src kinase. J Virol (1999) 1.07
Spontaneous loss of viral episomes accompanying Epstein-Barr virus reactivation in a Burkitt's lymphoma cell line. J Infect Dis (1998) 1.07
Variations among isolates of Epstein-Barr virus. Ann N Y Acad Sci (1980) 1.07
Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. J Gen Virol (1995) 1.06
Intrathecal production of antibodies against Toxoplasma gondii in patients with toxoplasmic encephalitis and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med (1988) 1.06
Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. J Virol (1995) 1.05
Transcription of Epstein-Barr virus latent cycle genes in oral hairy leukoplakia. Virology (1998) 1.04
Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression. J Virol (1998) 1.03
Epstein-Barr virus and epithelial cells: a possible role for the virus in the development of cervical carcinoma. Cancer Surv (1988) 1.02
Nucleotide dimers suppress HIV expression in vitro. AIDS Res Hum Retroviruses (1988) 1.02
In vitro suppression of HTLV-III/LAV infectivity by a combination of acyclovir and suramin. J Infect Dis (1986) 1.01
Detection of Epstein-Barr virus genome in ocular tissues. Ophthalmology (1996) 1.00